What We Do
BioAsset Advisors’ Prescription for Value
Many life sciences companies have limited internal resources and capabilities in performing fundamental opportunity assessments. BioAsset Advisors is experienced in working with life science companies to evaluate development and commercial options to drive growth and shareholder value.
BioAsset Advisors knows that no two companies’ needs are the same. An asset may be early or late stage; the company may be a privately held biotech or a global biopharma. The asset may be best suited to Rx or to OTC (or that decision may not yet have been taken).
Accordingly, we at BioAsset tailor our projects to our clients’ unique needs. We have the capabilities to provide a comprehensive range of services – but focus our approach and provide only those that are critical to achieving your goal – maximizing asset and shareholder value.